New nucleic acid diagnostic tests in viral hepatitis

Seminars in Liver Disease

Volumn 26, Issue 4, 2006, Pages 309-317

  Zoulim, Fabien ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

Antiviral therapy; Genotypes; Hepatitis B; Hepatitis C; Mutations; Viral genome; Viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

CHRONIC HEPATITIS; DRUG MONITORING; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVIEW; TREATMENT PLANNING; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS HEPATITIS; VIRUS LOAD; VIRUS MUTANT;

HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; NUCLEIC ACIDS;

EID: 33750344132     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951602     Document Type: Review

References (51)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68
2. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-693
3. Weiss J, Wu H, Farrenkopf B, et al. Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard. J Clin Virol 2004;30:86-93
4. Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol 2006;44:1390-1399
5. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536
6. Minuk GY, Sun DF, Uhanova J, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005;42:480-485
7. Miller RH, Robinson WS. Hepatitis B virus DNA in nuclear and cytoplasmic fractions of infected human liver. Virology 1984;137:390-399
8. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes ot hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985;5:728-734
9. Fourel I, Cullen JM, Saputelli J, et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994;68:8321-8330
10. Mason WS, Cullen J, Moraleda G, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998;245:18-32
11. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139-146
12. Kock J, Schlicht HG. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993;67:4867-4874
13. Addison WR, Wong WW, Fischer KP, Tyrrell DL. A quantitative competitive PCR assay for the covalently closed circular form of the duck hepatitis B virus. Antiviral Res 2000;48:27-37
14. He ML, Wu J, Chen Y, Lin MC, Lau GK, Kung HF. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun 2002;295:1102-1107
15. Kock J, Theilmann L, Galle P, Schlicht H. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 1996;23:405-413
16. Mason AL, Xu L, Guo L, Kuhns M, Perillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998;27:1736-1742
17. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758
18. Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727-737
19. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-1897
20. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-684
21. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129
22. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-1812
23. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-3734
24. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000;33:430-439
25. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088
26. Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol 2000;38:3022-3028
27. Tran N, Berne R, Chann R, et al. European multicenter evaluation of a high density DNA probe arrays for the detection of hepatitis B resistance mutations and identification of genotype. J Clin Microbiol 2006;44:2792-2800
28. Pang A, Yuen MF, Yuan HJ, Lai CL, Kwong YL. Real-time quantification of hepatitis B virus core-promoter and precore mutants during hepatitis E antigen seroconversion. J Hepatol 2004;40:1008-1017
29. Zhang M, Gong Y, Osiowy C, Minuk GY. Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis. Hepatology 2002;36:723-728
30. Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J Clin Microbiol 2001;39:1456-1459
31. Pichoud C, Seignères B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999;29:230-237
32. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633
33. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-1677
34. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006;26:171-180
35. Yang H, Westland C, Xiong S, Delaney WE. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004;61:27-36
36. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004;40:855-864
37. Durantel D, Brunelle MN, Gros E, et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005;34(suppl 1):S34-S43
38. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 2006; Apr 25 (Epub ahead of print)
39. Werle B, Cinquin K, Marcellin P, et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat 2004;11:74-83
40. Lai C, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine for chronic hepatitis B: first year results from the international phase III globe trial. Hepatology 2005;42(suppl 1):748A
41. Hadziyannis S, Tassopoulos N, Chang T, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology 2005;42 (suppl 1):745A
42. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-308
43. Halfon P, Bourliere M, Penaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006;44:2507-2511
44. Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005;9:371-382 v.
45. Comanor L, Elkin C, Leung K, et al. Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay. J Clin Virol 2003;28:14-26
46. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43(suppl 1):S207-S220
47. McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44:411-421
48. Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006;281:8205-8215
49. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909
50. Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80:6146-6154
51. Kim YJ, Kim SO, Chung HJ, et al. Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. Clin Chem 2005;51:1123-1131